Adaptive (ADPT) news
Recent news
Adaptive Biotechnologies Corp: TD Cowen raises target price to $28 from $25
AInvest Wire · Jul 30, 2026ADPT 2Q adj. EBITDA loss $0.73M, est. loss $3.75M
Adaptive Biotechnologies (Nasdaq: ADPT) reported a narrower-than-expected adjusted EBITDA loss of $0.73 million for the second quarter of 2024, significantly below the estimated loss of $3.75 million. The company’s MRD (Minimal Residual Disease) segment, which accounts for the majority of its…
AInvest Wire · Jul 29, 2026Adapthealth Corp: Jefferies raises to buy from hold; raises target price to $13 from $11
Jefferies has upgraded its rating for Adapthealth Corp (ADPT) from "hold" to "buy," reflecting a more favorable outlook on the company’s prospects. Alongside the rating change, the firm also raised its price target to $13 from $11. The adjustment follows a recent analysis of Adapthealth’s business…
AInvest Wire · Jul 21, 2026Adaptive reports plan to separate MRD, immune medicine business
Adaptive Biotechnologies has outlined plans to streamline its operations by separating its Minimal Residual Disease (MRD) and Immune Medicine business segments, according to recent disclosures. The move is part of a broader strategy to focus on core areas of growth and operational efficiency. The…
AInvest Wire · Jun 15, 2026ImportantAdaptive Biotechnologies Shares Fall 35% After Reviewing Alternatives
AInvest Wire · Nov 10, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.